Bicycle Therapeutics (BCYC) Shares Outstanding (Diluted Average) (2019 - 2026)

Bicycle Therapeutics has reported Shares Outstanding (Diluted Average) for 8 years, with the latest figure at $69.7 million in Q1 2026.

• For the quarter ending Q1 2026, Shares Outstanding (Diluted Average) rose 0.7% year-over-year to $69.7 million; the trailing twelve-month figure through Mar 2026 stood at $69.7 million (up 0.7% YoY), and the FY2025 full-year result was $69.3 million, up 19.02% from the prior year.
• Shares Outstanding (Diluted Average) for Q1 2026 stood at $69.7 million, up from $69.3 million in the prior quarter.
• The five-year high for Shares Outstanding (Diluted Average) was $69.7 million in Q1 2026, with the low at $29.6 million in Q1 2022.
• Historically, Shares Outstanding (Diluted Average) has averaged $47.7 million across 5 years, with a median of $42.6 million in 2024.
• Annual changes were most pronounced in 2024 — Shares Outstanding (Diluted Average) jumped 107.23% — and 2025, when it climbed 0.38%.
• Bicycle Therapeutics' Shares Outstanding (Diluted Average) stood at $29.7 million in 2022, then advanced by 20.0% to $35.6 million in 2023, then jumped by 63.54% to $58.2 million in 2024, then advanced by 19.02% to $69.3 million in 2025, then advanced by 0.58% to $69.7 million in 2026.
• The last three Shares Outstanding (Diluted Average) figures came in at $69.7 million (Q1 2026), $69.3 million (Q4 2025), and $69.3 million (Q3 2025), per Business Quant data.